article thumbnail

New Study to Examine Hypercortisolism in Resistant Hypertension

DAIC

tim.hodson Tue, 03/11/2025 - 11:19 Mar. 10, 2025-- Corcept Therapeutics Inc., tim.hodson Tue, 03/11/2025 - 11:19 Mar. 10, 2025-- Corcept Therapeutics Inc., will establish the prevalence of endogenous hypercortisolism in patients with resistant hypertension.

article thumbnail

GOLD 2025 Report: Addressing Heart Disease in COPD

HCPLive

Key treatable traits in COPD-associated pulmonary hypertension include hypoxemia, inflammation, and right ventricular dysfunction. In stable COPD, cardiovascular complications are a leading cause of mortality, whereas acute exacerbations can worsen heart function.

article thumbnail

Medtronic Presents New Data, Clinical Milestones at CRT 2025

DAIC

tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.

article thumbnail

Renal denervation for hypertension

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 02 January 2025; doi:10.1038/s41569-024-01104-z Endovascular renal denervation has been approved for the treatment of hypertension.

article thumbnail

How to Choose the Right Patient Engagement Platform for Your Cardiology Practice in 2025

GEMMS

In 2025, the world of healthcare is changing daily, and nowhere is this more apparent than in cardiology. In 2025, the demand for telehealth capabilities will only continue to grow, especially in managing chronic conditions like hypertension and heart disease.

article thumbnail

FDA Approves Updated Label for Tryvio (aprocitentan)

DAIC

tim.hodson Wed, 04/09/2025 - 14:38 April 9, 2025 Idorsia Ltd recently announced that the US Food & Drug Administration (FDA), after having released Tryvio from its REMS (Risk Evaluation and Mitigation Strategy) requirement ( announced March 17, 2025 ), has now approved the updated label for Tryvio(aprocitentan). Hypertension.

article thumbnail

Clinical Study Highlights Research on AI that Takes on Cardiopulmonary Killer

DAIC

tim.hodson Mon, 02/10/2025 - 12:43 Feb. 6, 2025 Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, recently announcedpublication of a peer-reviewed study evaluating its novel algorithm for the detection of pulmonary hypertension (PH).